Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07893054) titled 'A First-in-human Clinical Trial to Test if the Investigational Drug BNT3219 is Safe and Potentially Beneficial for People With Advanced Solid Tumors When Given Alone or Together With Other Investigational Drugs' on Oct. 19.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: BioNTech SE

Condition: Advanced Solid Tumors

Intervention: Drug: BNT3219

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: November 2026

Target Sample Size: 207

To know more, vi...